An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab
NCT02507752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94
Last updated 2016-02-02
Summary
This multicenter prospective observational study will evaluate the quality of life in participants with rheumatoid arthritis (RA) who are initiated with rituximab (MabThera/Rituxan). Participants will be followed for 6 months from initiation of treatment.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-07-31
- Primary Completion
- 2012-06-30
- Completion
- 2012-06-30
Countries
- Brazil
Study Locations
More Related Trials
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
NCT01196780 ·Status: TERMINATED
-
A Study on Rheumatoid Arthritis Patients Treated With Rituximab
NCT02622503 ·Status: COMPLETED
-
Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate
NCT02641977 ·Status: COMPLETED
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
NCT01641952 ·Status: COMPLETED
-
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
NCT02006706 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
NCT01557348 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
NCT02097745 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
NCT00424502 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
NCT01613027 ·Status: COMPLETED
-
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
NCT02093026 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
NCT02079532 ·Status: COMPLETED ·Phase: PHASE3
-
PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis
NCT02819726 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
NCT00502840 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
NCT00074438 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis
NCT00299130 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis
NCT02699892 ·Status: COMPLETED
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
NCT01309282 ·Status: COMPLETED
-
An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy
NCT01592292 ·Status: COMPLETED
-
Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
NCT02296775 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
NCT01526057 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
NCT00503425 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker
NCT02322801 ·Status: COMPLETED
-
An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
NCT01283399 ·Status: COMPLETED
-
A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea
NCT01294722 ·Status: COMPLETED
-
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
NCT00299104 ·Status: COMPLETED ·Phase: PHASE3